401results about How to "Minimize side effects" patented technology

A water soluble biodegradable ABA- or BAB-type triblock polymer is disclosed that is made up of a major amount of a hydrophobic polymer made of a poly(lactide-co-glycolide) copolymer or poly(lactide) polymer as the A-blocks and a minor amount of a hydrophilic polyethylene glycol polymer B-block, having an overall weight average molecular weight of between about 2000 and 4990, and that possesses reverse thermal gelation properties. Effective concentrations of the triblock polymer and a drug may be uniformly contained in an aqueous phase to form a drug delivery composition. At temperatures below the gelation temperature of the triblock polymer the composition is a liquid and at temperatures at or above the gelation temperature the composition is a gel or semi-solid. The composition may be administered to a warm-blooded animal as a liquid by parenteral, ocular, topical, inhalation, transdermal, vaginal, transurethral, rectal, nasal, oral, pulmonary or aural delivery means and is a gel at body temperature. The composition may also be administered as a gel. The drug is released at a controlled rate from the gel which biodegrades into non-toxic products. The release rate of the drug may be adjusted by changing various parameters such as hydrophobic/hydrophilic componenet content, polymer concentration, molecular weight and polydispersity of the triblock polymer. Because the triblock polymer is amphiphilic, it functions to increase the solubility and/or stability of drugs in the composition.

This invention relates to methods and compositions for treating psychiatric conditions, such as depression.

Omega-3 fatty acid compositions comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are provided, where the compositions are useful for treating, reducing the occurrence of, or preventing major adverse cardiovascular events or major coronary events in patients who have established cardiovascular disease without prior myocardial infarction, preventing their further progression, and treating underlying risk factors for CVD such as hypertension, dyslipidemia, obesity and/or diabetes.

Methods of medical treatment and diagnosis using mediators released by endothelial cells stimulated by external addition of pulses to the circulation are disclosed. The external pulses produce circumferential shear stress in body fluid channels that subsequently stimulates the endothelial cells to produce mediators that become available for therapeutic and diagnostic purposes. The preferred means of adding external pulses is the mechanical inducement of periodic acceleration of the body or parts of the body by a reciprocating motion platform.

The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.

A water soluble, biodegradable reverse thermal gelation system comprising a mixture of at least two types of tri-block copolymer components is disclosed. The tri-block copolymer components are made of a hydrophobic biodegradable polyester A-polymer block and a hydrophilic polyethylene glycol B-polymer block. The drug release and gel matrix erosion rates of the biodegradable reverse thermal gelation system may be modulated by various parameters such as the hydrophobic/hydrophilic component contents, polymer block concentrations, molecular weights and gelation temperatures, and weight ratios of the tri-block copolymer components in the mixture.

Various methods and apparatus for treating a condition associated with impaired glucose regulation in a subject comprising in one embodiment, applying a neural conduction block to a target nerve at a blocking site with the neural conduction block selected to at least partially block nerve pulses. In another embodiment, combinations of down-regulating and or up-regulating with or without pharmaceutical agents are used to treat impaired glucose regulation. In other embodiments, up-regulation or down-regulation of various nerves, such as the vagus and its branches, and the splanchnic is used to modify the production of GLP-1 and GIP, thereby controlling glucose levels. In yet further embodiments, combinations of down-regulating and or up-regulating with or without pharmaceutical agents are used to modify the production of GLP-1 and GIP, to treat impaired glucose regulation.

A modified release preparation having one or more coated core elements, each core element including an active ingredient and having a modified release coating, wherein a stabilising coat is provided between each core element and its modified release coating so that, upon in vitro dissolution testing, the amount of active ingredient released at any time on a post-storage dissolution profile is within 40 percentage points of the amount of active ingredient released at any time on a pre-storage dissolution profile.

Medical devices with at least one surface comprising a polymer or polymers on the surface are provided. The polymer or polymers are capable of breaking down (e.g., including, but not limited to, hydrolyzing) in the physiologic milieu to form an active agent or agents under physiologic conditions, and can contain other active agents dispersed within or appended to the polymer matrix. Methods of delivering an active agent to an interior surface of a vein or artery are also provided.

Devices, systems and methods for treating pain or other conditions while minimizing possible complications and side effects. Treatment typically includes electrical stimulation and/or delivery of pharmacological or other agents with the use of a lead or catheter. The devices, systems and methods provide improved anchoring which reduces migration of the lead yet allows for easy repositioning or removal of the lead if desired. The devices, systems and methods also provide for simultaneous treatment of multiple targeted anatomies. This shortens procedure time and allows for less access points, such as needle sticks to the epidural space, which in turn reduces complications, such as cerebral spinal fluid leaks, patient soreness and recovery time. Other possible complications related to the placement of multiple devices are also reduced.

A method of inhibiting the growth of refractory tumors that are stimulated by mitogenic ligands of epidermal growth factor receptor in human patients, comprising treating the human patients with an effective amount of a mitogenic ligand antagonist.

This invention provides an aerosolized inhaler which enables the drug powder to aerosolize within the inhaler by breathing in the air, comprising the main body (11) and the mouthpiece connector (12) connected thereupon, wherein the inhaler the main body (11) has drug holding opening (1), which connects with the vortex passage, and the vortex passage connects with the mouthpiece (9) on the mouthpiece connector (12). It has many obvious advantages as increasing the inhalation rate, pushing more drug granule to reach to the lower respiratory tract and even into the alveolus; and meanwhile, keeping the drug from being blown out of the inhaler when the users breathes out, preventing from cross inflection and minimizing the side effect of the drug to the whole body, and obviously lightening the burden on the users.

Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.

The present invention provides methods and compositions for modulating levels of amyloid-beta peptide (Abeta) exhibited by cells or tissues. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate Abeta levels. The invention also provides modulation of Abeta levels via selective modulation (e.g., inhibition) of ATP-dependent gamma-secretase activity. The invention also provides methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an Abeta-related disorder, by administering a modulator of gamma-secretase, including, but not limited to, a selective inhibitor of ATP-dependent gamma-secretase activity or an agent that decreases the formation of active (or optimally active) gamma-secretase. The invention also provides the use of inhibitors of ATP-dependent gamma-secretase activity to prevent, treat or ameliorate the symptoms of Alzheimer's disease.

Methods and medical devices for treating a proliferative disorder in a subject, e.g., restenosis in a blood vessel that has been implanted with a stent, employ a bis(thio-hydrazide amide) represented by Structural Formula I or a pharmaceutically acceptable salt or solvate thereof.

Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group.

R₁-R₄ are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R₁ and R₃ taken together with the carbon and nitrogen atoms to which they are bonded, and/or R₂ and R₄ taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.

R₇-R₈ are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.

The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.

Systems and methods are described for using methylnaltrexone to treat or prevent inhibition of gastrointestinal motility in equines. A method for preventing or treating opioid-induced and non-opioid-induced gastrointestinal dysfunction includes administering a quaternary derivative of noroxymorphone, preferably methylnaltrexone, to an equine before or after the onset of the gastrointestinal dysfunction.